A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.

Mark Milton – Edwards Global Dir. Respiratory, TEVA

FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.

Mark Milton – Edwards Global Dir. Respiratory, TEVA

FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

Exciting new results will be presented at the upcoming European Respiratory Society Conference in Milan from 9-13 September! The primary
Read More
" We were very impressed by the additional insights FRI brought to this clinical trial. The FRI data gave us confidence
Read More
"The U.S. Food and Drug Administration approved the design of a Phase 2b trial of INOpulse, a device that delivers
Read More
Chronic rejection or Bronchiolitis Obliterans Syndrome (BOS) remains the most important cause of death in lung transplant patients. Diagnosing BOS
Read More